IP Library Granted Patent US 8,324,197
Granted Patent B2
US 8,324,197 · App. 11/502,621 · Granted Dec 4, 2012

Transplatinum complexes with N

Assignee: Virginia Commonwealth University
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,324,197
App. No.
11/502,621
Granted
Dec 4, 2012
Kind
B2
Abstract

Trans-platinum compounds comprising carboxylato groups are disclosed, with anti-cancer usefulness. The carboxylato groups participate in solubilizing trans-platinum compounds to which they are attached.

Claims (74)

1. A trans-platinum (II) complex of formula trans-[Pt(carboxylato) 2 (L)(L′)] where carboxylato =a ligand derived from an anion of a carboxylic acid, and wherein said trans-platinum (II) complex is represented by formula (I) as follows:

wherein

i) RCOO— is a carboxylate anion of a carboxylic acid and R is H or an alkyl group which may be substituted or unsubstituted; and

ii) L and L′ are both planar heterocyclic amines, or

one of L or L′ is a planar heterocyclic amine and the other is selected from the group consisting of NH 3 a branched aliphatic amine, an iminoether, a primary amine, a secondary amine and an aliphatic nitrogen-containing heterocycle.

2. The trans-platinum (II) complex of claim 1 , wherein L is a planar amine and L′ is NH 3 .

3. The trans-platinum (II) complex of claim 1 , wherein the aliphatic nitrogen-containing heterocycle is selected from the group consisting of piperazine, piperidine and pyrazole.

4. The trans-platinum(II) complex of claim 1 , wherein said carboxylato ligand is selected from the group consisting of formate, acetate, hydroxyacetate, chloroacetate, trifluoroacetate and lactate including optical isomers thereof.

5. The trans-platinum (II) complex of claim 1 , wherein said planar heterocyclic amine is selected from the group consisting of pyridine, substituted pyridines, quinoline, subsituted quinolines, isoquinoline, substituted isoquinolines, thiazole, and substituted thiazoles.

6. The trans-platinum (U) complex of claim 1 , wherein R is H or an alkyl group which may be substituted or unsubstituted.

7. The trans-platinum (II) complex of claim 1 , wherein L or L′ is substituted with a substituent selected from the group consisting of Me, Br, Cl and F.

8. The trans-platinum (II) complex of claim 1 , wherein said trans-platinum (II) complex is selected from the group consisting of:

trans-[Pt(OAc) 2 (NH 3 )(py)]

trans-[Pt(OAc) 2 (NH 3 )(2Me-py)]

trans-[Pt(OAc) 2 (NH 3 )(3Me-py)]

trans-[Pt(OAc) 2 (NH 3 )(4Me-py)]

trans-[Pt(OAc) 2 (NH 3 )(tz)]

trans-[Pt(OAc) 2 (NH 3 )(quin)]

trans-[Pt(OAc) 2 (NH 3 )(Iq)]

trans-[Pt(OFm) 2 (NH 3 )(py)]

trans-[Pt(OFm) 2 (NH 3 )(2Me-py)]

trans-[Pt(OFm) 2 (NH 3 )(3Me-py)]

trans-[Pt(OFm) 2 (NH 3 )(4Me-py)]

trans-[Pt(OFm) 2 (NH 3 )(tz)]

trans-[Pt(OFm) 2 (NH 3 )(quin)]

trans-[Pt(OFm) 2 (NH 3 )(Iq)]

trans-[Pt(lact) 2 (NH 3 )(py)]

trans-[Pt(lact) 2 (NH 3 )(2Me-py)]

trans-[Pt(lact) 2 (NH 3 )(3Me-py)]

trans-[Pt(lact) 2 (NH 3 )(4Me-py)]

trans-[Pt(lact) 2 (NH 3 )(tz)]

trans-[Pt(lact) 2 (NH 3 )(quin)]

trans-[Pt(lact) 2 (NH 3 )(Iq)]

trans-[Pt(OAcOH) 2 (NH 3 )(py)]

trans-[Pt(OAcOH) 2 (NH 3 )(2Me-py)]

trans-[Pt(OAcOH) 2 (NH 3 )(3Me-py)]

trans-[Pt(OAcOH) 2 (NH 3 )(4Me-py)]

trans-[Pt(OAcOH) 2 (NH 3 )(tz)]

trans-[Pt(OAcOH) 2 (NH 3 )(quin)]

trans-[Pt(OAcOH) 2 (NH 3 )(Iq)]

trans-[Pt(TFA) 2 (NH 3 )(py)]

trans-[Pt(TFA) 2 (NH 3 )(2Me-py)]

trans-[Pt(TFA) 2 (NH 3 )(3Me-py)]

trans-[Pt(TFA) 2 (NH 3 )(4Me-py)]

trans-[Pt(TFA) 2 (NH 3 )(py)]

trans-[Pt(TFA) 2 (NH 3 )(quin)]

trans-[Pt(TFA) 2 (NH 3 )(Iq)]

trans-[Pt(OAc) 2 (py) 2 ]

trans-[Pt(OAc) 2 (2Me-py) 2 ]

trans-[Pt(OAc) 2 (3Me-py) 2 ]

trans-[Pt(OAc) 2 (4Me-py) 2 ]

trans-[Pt(OAc) 2 (tz) 2 ]

trans-[Pt(OFm) 2 (py) 2 ]

trans-[Pt(OFm) 2 (2Me-py) 2 ]

trans-[Pt(OFm) 2 (3Me-py) 2 ]

trans-[Pt(OFm) 2 (4Me-py) 2 ]

trans-[Pt(OFm) 2 (tz) 2 ]

trans-[Pt(lact) 2 (py) 2 ]

trans-[Pt(lact) 2 (2Me-py) 2 ]

trans-[Pt(lact) 2 (3Me-py) 2 ]

trans-[Pt(lact) 2 (4Me-py) 2 ]

trans-[Pt(lact) 2 (tz) 2 ]

trans-[Pt(OAcOH) 2 (py) 2 ]

trans-[Pt(OAcOH) 2 (2Me-py) 2 ]

trans-[Pt(OAcOH) 2 (3Me-py) 2 ]

trans-[Pt(OAcOH) 2 (4Me-py) 2 ]

trans-[Pt(OAcOH) 2 (tz) 2 ]

trans-[Pt(TFA) 2 (py) 2 ]

trans-[Pt(TFA) 2 (2Me-py) 2 ]

trans-[Pt(TFA) 2 (3Me-py) 2 ]

trans-[Pt(TFA) 2 (4Me-py) 2 ] and

trans-[Pt(TFA) 2 (tz) 2 ]

wherein

OAc=acetate CH 3 COO − ; OFm=formate HCOO − ; Lact=lactate CH 3 C.H(OH)COO − (.=R or S chirality); OAcOH=hydroxyacetate HOCH 2 COO − ; TFA=trifluoroacetate CF 3 COO − ; py=pyridine; 2Me-py=2-methylpyridine; 3Me-py=3-methylpyridine; 4Me-py=4-methylpyridine; tz=thiazole; Iq=isoquinoline; and quin=quinoline.

Assignments (2)
CONFIRMATORY LICENSE Recorded Jun 14, 2016
From: VIRGINIA COMMONWEALTH UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 038984/0302 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 27, 2006
From: FARRELL, NICHOLAS P.
To: VIRGINIA COMMONWEALTH UNIVERSITY
Reel/Frame 018682/0544 →
Continuity (2)
Provisional Application 60707176 · Aug 11, 2005
Related Publication 20070082882A1 · Apr 12, 2007